Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 03/10/15 | SC 13G/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
13 | |
| 03/05/15 | 8-K | Current report filing |
|
4 | |
| 02/26/15 | 8-K | Current report filing |
|
5 | |
| 02/20/15 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
33 | |
| 02/18/15 | 8-K | Current report filing |
|
3 | |
| 02/18/15 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
59 | |
| 02/18/15 | 8-K | Current report filing |
|
29 | |
| 02/17/15 | EFFECT | Notice of Effectiveness |
|
1 | |
| 02/17/15 | SC 13G/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
9 | |
| 02/17/15 | S-1/A | General form of registration statement for all companies including face-amount certificate companies |
|
146 |
